Eli Lilly (LLY) shares declined in premarket trading following a pricing announcement from primary rival Novo Nordisk. Novo Nordisk plans to reduce prices for its Wegovy and Ozempic weight-loss drugs by 35% to 50%. These price reductions are scheduled to begin in 2027.
The market reaction overshadowed the launch of Lilly’s new four-dose KwikPen for Zepbound. This single-patient delivery system aims to improve patient convenience and adherence.
Lilly’s clinical position remains robust despite the competitive pricing pressure. A late-stage trial recently showed that a next-generation obesity drug from Novo Nordisk failed to outperform Lilly’s tirzepatide.